Molecular diagnostics company Genetic Signatures (ASX:GSS) announced an expansion of its European footprint, signing a multi-year supply agreement with Hvidovre Hospital, one of Denmark’s premier public healthcare institutions.
The deal centres on the implementation of the company's proprietary 3Base EasyScreen Pan-Enteric detection kit, a high-throughput automated solution designed to identify 24 gastrointestinal pathogens simultaneously.
The partnership includes a ten-year reagent supply agreement and an equipment lease expected to span at least eight years.
Operations are slated to commence in September, with the hospital projected to process approximately 28,000 samples in the first year alone.
The transition to a streamlined, multiplex PCR workflow replaces traditional, fragmented diagnostic methods such as culturing and ELISA.
By consolidating the complex algorithms into a single automated system, the hospital aims to significantly reduce laboratory turnaround times and staffing requirements.
Beyond laboratory efficiency, the "pan-enteric" approach offers substantial clinical advantages.
Previous implementations in the United Kingdom demonstrated that rapid, accurate screening leads to a tripling of diagnostic yield and a marked decline in Clostridioides difficile infections.
For the broader hospital environment, these improved infection-control measures are expected to reduce ward closures, shorten patient stays, and enable more targeted antibiotic use.
At the time of reporting, Genetic Signatures’ share price was $0.10.